abciximab /ab-sik′si-mab/ , a human-murine monoclonal antibody Fab fragment that inhibits the aggregation of platelets, used in the prevention of thrombosis in percutaneous transluminal coronary angioplasty, administered by intravenous infusion. ▪ INDICATIONS: It is prescribed as an adjunct to percutaneous transluminal coronary angioplasty or atherectomy. ▪ CONTRAINDICATIONS: The drug should not be given to patients with active internal bleeding, recent GI or urinary bleeding of significance, history of stroke, thrombocytopenia, or recent major surgery. ▪ ADVERSE EFFECTS: The side effects most often reported include bleeding, thrombocytopenia, pulmonary edema, atrioventricular block, and atrial fibrillation.
